Patents by Inventor Sarah F. Hamm-Alvarez

Sarah F. Hamm-Alvarez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIMERIC ELASTIN-LIKE POLYPEPTIDES
    Publication number: 20230181752
    Abstract: This disclosure provides a novel compositions and methods to deliver cyclosporine A using genetically engineered protein polymers.
    Type: Application
    Filed: October 10, 2022
    Publication date: June 15, 2023
    Inventors: John Andrew Mackay, Mihir Shah, Sarah F. Hamm-Alvarez, Hao Guo, Santosh Peddi
  • Multimeric elastin-like polypeptides
    Patent number: 11464867
    Abstract: This disclosure provides a novel compositions and methods to deliver cyclosporine A using genetically engineered protein polymers.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 11, 2022
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: John Andrew Mackay, Mihir Shah, Sarah F. Hamm-Alvarez, Hao Guo, Santosh Peddi
  • MULTIMERIC ELASTIN-LIKE POLYPEPTIDES
    Publication number: 20190282656
    Abstract: This disclosure provides a novel compositions and methods to deliver cyclosporine A using genetically engineered protein polymers.
    Type: Application
    Filed: February 12, 2019
    Publication date: September 19, 2019
    Inventors: John Andrew Mackay, Mihir Shah, Sarah F. Hamm-Alvarez, Hao Guo, Santosh Peddi
  • ICAM-1 TARGETING ELPS
    Publication number: 20190247317
    Abstract: Provided herein are therapeutic agents comprising an elastin-like peptide (ELP) component and a ligand that specifically targets and binds an ICAM-1 receptor. In one aspect, the ELP comprises, or alternatively consists essentially of, or yet further consists of one or more sequence(s) designated S48I48 and/or mICMA-1 SI and/or hICAM-1 S1 or biological equivalents thereof. In a further aspect, the ELP/ligand composition further comprises a therapeutic agent. In one aspect, the therapeutic agent is specific to the treatment or amelioration of symptoms associated with autoimmune disorders such as SjS.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 15, 2019
    Inventors: Sarah F. Hamm-Alvarez, John Andrew MacKay, Pang-Yu Hsueh
  • ICAM-1 TARGETING ELPS
    Publication number: 20150238431
    Abstract: Provided herein are therapeutic agents comprising an elastin-like peptide (ELP) component and a ligand that specifically targets and binds an ICAM-1 receptor. In one aspect, the ELP comprises, or alternatively consists essentially of, or yet further consists of one or more sequence(s) designated S48I48 and/or mICMA-1 SI and/or hICAM-1 S1 or biological equivalents thereof. In a further aspect, the ELP/ligand composition further comprises a therapeutic agent. In one aspect, the therapeutic agent is specific to the treatment or amelioration of symptoms associated with autoimmune disorders such as SjS.
    Type: Application
    Filed: April 10, 2015
    Publication date: August 27, 2015
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Sarah F. Hamm-Alvarez, John Andrew MacKay, Pang-Yu Hsueh
  • METHODS AND SMALL MOLECULE THERAPEUTICS COMPRISING FUSED ELPS
    Publication number: 20150209335
    Abstract: This disclosure provides a novel compositions and methods to deliver small molecule therapeutics using genetically engineered protein polymers connected to the ‘cognate’ human protein target of that drug.
    Type: Application
    Filed: April 9, 2015
    Publication date: July 30, 2015
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: John Andrew MacKay, Sarah F. Hamm-Alvarez, Pu Shi, Jugal P. Dhandhukia, Mihir K. Shah